Comparative proteomic analyses of urine from rat urothelial carcinoma chemically induced by exposure to N-butyl-N-(4-hydroxybutyl)-nitrosamine

Ferreira, Rita; Oliveira, Paula A.; Martins, Telma; Magalhães, Sandra; Trindade, Fábio; Pires, Maria dos Anjos; Colaço, Bruno; Barros, António S.; Santos, Lúcio Lara; Amado, Francisco; Vitorino, Rui

doi:10.1039/c4mb00606b

Cited by 9 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…stimuli that provoke subclinical chronic inflammation leading to fibrosis with remodeling of the extracellular matrix (ECM) resulting into a precancerous niche (PCN) [27]. Proteomic analysis can help to identify biological processes that could be of importance in carcinogenesis [28]. Schistosoma haematobium was associated with bladder cancer using proteomic profiling [29].…”

Section: Microbiome (Tab 1)mentioning

confidence: 99%

Microbiome and morbid obesity increase pathogenic stimulus diversity

Brücher

Jamall

2019

4open

View full text Add to dashboard Cite

The microbiome, the relationship between environmental factors, a high-fat diet, morbid obesity, and host response have been associated with cancer, only a small fraction of which (<10%) are genetically triggered. This nongenetic association is underpinned by a worldwide increase in morbid obesity, which is associated with both insulin resistance and chronic inflammation. The connection of the microbiome and morbid obesity is reinforced by an approximate shift of about 47% in the estimated total number of bacteria and an increase from 38,000,000,000,000 in a reference man to 56,000,000,000,000 in morbid obesity leading to a disruption of the microbial ecology within the gut. Humans contain 6,000,000,000 microbes and more than 90% of the cells of the human body are microorganisms. Changes in the microflora of the gut are associated with the polarization of ion channels by butyrate, thereby influencing cell growth. The decrease in the relative proportion of Bacteroidetes together with a change in the fermentation of carbohydrates by bacteria is observed in morbid obesity. The disruption of homeostasis of the microflora in the obese changes signaling and crosstalk of several pathways, resulting in inflammation while suppressing apoptosis. The interactions between the microbiome and morbid obesity are important to understand signaling and crosstalk in the context of the progression of the six-step sequence of carcinogenesis. This disruption of homeostasis increases remodeling of the extracellular matrix and fibrosis followed by the none-resolvable precancerous niche as the internal pathogenic stimuli continue. The chronic stress explains why under such circumstances there is a greater proclivity for normal cells to undergo the transition to cancer cells.

show abstract

Section: Microbiome (Tab 1)mentioning

confidence: 99%

Microbiome and morbid obesity increase pathogenic stimulus diversity

Brücher

Jamall

2019

4open

View full text Add to dashboard Cite

show abstract

“…Female SD rats were anesthetized using ether inhalation, and their bladders were infused using 0.2 ml N -methyl-Nnitrosurea (MNU) (10 mg/mL; Sigma, St. Louis, MO, USA,) using a 22-gage angiocatheter one every 14 days five times. After catheterization, the rats remained anesthetized for approximately 45 min to avoid spontaneous micturition [ 35 , 36 ].…”

Section: Methodsmentioning

confidence: 99%

Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer

et al. 2021

View full text Add to dashboard Cite

Background For certain human cancers, sperm associated antigen 5 (SPAG5) exerts important functions for their development and progression. However, whether RNA interference (RNAi) targeting SPAG5 has antitumor effects has not been determined clinically. Results The results indicated that Fe-doped chrysotile nanotubes (FeSiNTs) with a relatively uniform outer diameter (15–25 nm) and inner diameter (7–8 nm), and a length of several hundred nanometers, which delivered an siRNA against the SPAG5 oncogene (siSPAG5) efficiently. The nanomaterials were designed to prolong the half-life of siSPAG5 in blood, increase tumor cell-specific uptake, and maximize the efficiency of SPAG5 silencing. In vitro, FeSiNTs carrying siSPAG5 inhibited the growth, migration, and invasion of bladder cancer cells. In vivo, the FeSiNTs inhibited growth and metastasis in three models of bladder tumors (a tail vein injection lung metastatic model, an in-situ bladder cancer model, and a subcutaneous model) with no obvious toxicities. Mechanistically, we showed that FeSiNTs/siSPAG5 repressed PI3K/AKT/mTOR signaling, which suppressed the growth and progression of tumor cells. Conclusions The results highlight that FeSiNTs/siSPAG5 caused no activation of the innate immune response nor any systemic toxicity, indicating the possible therapeutic utility of FeSiNTs/siSPAG5 to deliver siSPAG5 to treat bladder cancer. Graphic abstract

show abstract

“…Body fluids including serum and plasma might be better choices not only for discovery studies but also for evaluation of patient’s response to a therapeutic reagent since they can be accessed readily [ 122 , 123 ]. On the other hand, cancer cell lines were developed and analyzed to identify proteins differentially expressed in vitro, which provides an easier and faster way to discover and develop cancer-specific biomarkers [ 124 , 125 ].…”

Section: Proteomicsmentioning

confidence: 99%

Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers

Brücher

Schnabel³

et al. 2016

Clinical & Translational Med

View full text Add to dashboard Cite

One major objective for our evolving understanding in the treatment of cancers will be to address how a combination of diagnosis and treatment strategies can be used to integrate patient and tumor variables with an outcome-oriented approach. Such an approach, in a multimodal therapy setting, could identify those patients (1) who should undergo a defined treatment (personalized therapy) (2) in whom modifications of the multimodal therapy due to observed responses might lead to an improvement of the response and/or prognosis (individualized therapy), (3) who might not benefit from a particular toxic treatment regimen, and (4) who could be identified early on and thereby be spared the morbidity associated with such treatments. These strategies could lead in the direction of precision medicine and there is hope of integrating translational molecular data to improve cancer classifications. In order to achieve these goals, it is necessary to understand the key issues in different aspects of biotechnology to anticipate future directions of personalized and individualized diagnosis and multimodal treatment strategies. Providing an overview of translational data in cancers proved to be a challenge as different methods and techniques used to obtain molecular data are used and studies are based on different tumor entities with different tumor biology and prognoses as well as vastly different therapeutic approaches. The pros and cons of the available methodologies and the potential response data in genomics, microRNA, epigenetics and proteomics with a focus on upper gastrointestinal cancers are considered herein to allow for an understanding of where these technologies stand with respect to cancer diagnosis, prognosis and treatment.

show abstract

Comparative proteomic analyses of urine from rat urothelial carcinoma chemically induced by exposure to N-butyl-N-(4-hydroxybutyl)-nitrosamine

Cited by 9 publications

References 38 publications

Microbiome and morbid obesity increase pathogenic stimulus diversity

Microbiome and morbid obesity increase pathogenic stimulus diversity

Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer

Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers

Contact Info

Product

Resources

About